DC AMS PHARMA

In 2006, DC AMS PHARMA was established with the development direction of "Early Diagnosis · Precision Therapy". Its mission is to promote the popularization and application of non powered civilian nuclear technology in the medical field, and to build an industry recognized excellent enterprise, making special contributions to promoting people's health.

DC AMS PHARMA is a leading enterprise in the networked production and distribution of radioactive drugs in China, Basically covers the nuclear medicine needs of 93.5% of the domestic population.

DC AMS PHARMA is a nuclear medical innovation technology enterprise, a high-tech enterprise, a technology-based gazelle enterprise, and a provincial specialized, refined, and new enterprise; Provincial enterprise technology center and graduate workstation. In 2018, it was acquired by Dongcheng Pharmaceutical (SZ002675) and became a wholly-owned subsidiary of Dongcheng Pharmaceutical.